RU2000103824A - Adipocyte-Specific Protein Homologues - Google Patents
Adipocyte-Specific Protein HomologuesInfo
- Publication number
- RU2000103824A RU2000103824A RU2000103824/13A RU2000103824A RU2000103824A RU 2000103824 A RU2000103824 A RU 2000103824A RU 2000103824/13 A RU2000103824/13 A RU 2000103824/13A RU 2000103824 A RU2000103824 A RU 2000103824A RU 2000103824 A RU2000103824 A RU 2000103824A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- seq
- polypeptide
- sequence
- residues
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 5
- 108090000623 proteins and genes Proteins 0.000 title claims 5
- 229920001184 polypeptide Polymers 0.000 claims 47
- 125000000539 amino acid group Chemical group 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 229920000023 polynucleotide Polymers 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 11
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 102000008186 Collagen Human genes 0.000 claims 8
- 108010035532 Collagen Proteins 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 229920001436 collagen Polymers 0.000 claims 8
- 229960005188 collagen Drugs 0.000 claims 8
- 230000035897 transcription Effects 0.000 claims 6
- 235000004559 haa Nutrition 0.000 claims 5
- 235000009424 haa Nutrition 0.000 claims 5
- 230000003248 secreting Effects 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 3
- 230000000295 complement Effects 0.000 claims 2
- 238000006471 dimerization reaction Methods 0.000 claims 2
- 238000006384 oligomerization reaction Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 210000004748 cultured cells Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002797 proteolythic Effects 0.000 claims 1
- -1 radionuclides Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
Claims (31)
a) полипептида, имеющего последовательность аминокислотных остатков, которая является на 75% идентичной по последовательности аминокислот аминокислотным остаткам 99-140 SEQ ID NO:2;
b) полипептида, имеющего последовательность аминокислотных остатков, которая является на 75% идентичной по последовательности аминокислот аминокислотным остаткам 140- или 141-281 SEQ ID NO:2; и
c) полипептида, имеющего последовательность аминокислотных остатков, которая является на 75% идентичной по последовательности аминокислот аминокислотным остаткам 99-281 SEQ ID NO:2.6. The selected polypeptide selected from the group consisting of:
a) a polypeptide having an amino acid residue sequence that is 75% identical in amino acid sequence to amino acid residues 99-140 of SEQ ID NO: 2;
b) a polypeptide having an amino acid residue sequence that is 75% identical in amino acid sequence to amino acid residues 140 or 141-281 of SEQ ID NO: 2; and
c) a polypeptide having an amino acid residue sequence that is 75% identical in amino acid sequence to amino acid residues 99-281 of SEQ ID NO: 2.
a) полипептида, содержащего последовательность аминокислотных остатков, которая является по меньшей мере на 75% идентичной по последовательности аминокислот аминокислотным остаткам 26-281 SEQ ID NO:2;
b) полипептида, содержащего последовательность аминокислотных остатков, показанную в SEQ ID NO:2, от аминокислотного остатка 1, 22 или 26 до аминокислотного остатка 281;
c) полипептида, содержащего последовательность аминокислотных остатков, показанную в SEQ ID NO:44, от аминокислотного остатка 1,22 или 26 до аминокислотного остатка 281;
d) части полипептида zsig37, показанной в SEQ ID NO:2 или SEQ ID NO:44, содержащей коллагеноподобный домен или часть коллагеноподобного домена, способную к димеризации или олигомеризации;
e) части полипептида zsig37, показанной в SEQ ID NO:2 или SEQ ID NO:44, содержащей подобный глобулярному домен или активную часть подобного глобулярному домена; или
f) части полипептида zsig37, показанной в SEQ ID NO:2 или SEQ ID NO:44, включающей в себя коллагеноподобный домен и глобулярный домен; и
указанная вторая часть содержит другой полипептид.7. A hybrid protein consisting essentially of the first part and the second part connected by a peptide bond, and the specified first part contains a polypeptide selected from the group consisting of:
a) a polypeptide containing a sequence of amino acid residues that is at least 75% identical in amino acid sequence to amino acid residues 26-281 of SEQ ID NO: 2;
b) a polypeptide containing the sequence of amino acid residues shown in SEQ ID NO: 2, from amino acid residue 1, 22 or 26 to amino acid residue 281;
c) a polypeptide containing the sequence of amino acid residues shown in SEQ ID NO: 44, from amino acid residue 1,22 or 26 to amino acid residue 281;
d) a portion of the zsig37 polypeptide shown in SEQ ID NO: 2 or SEQ ID NO: 44 containing a collagen-like domain or a portion of a collagen-like domain capable of dimerization or oligomerization;
e) a portion of the zsig37 polypeptide shown in SEQ ID NO: 2 or SEQ ID NO: 44, containing a globular-like domain or an active portion of a globular-like domain; or
f) a portion of the zsig37 polypeptide shown in SEQ ID NO: 2 or SEQ ID NO: 44, including a collagen-like domain and a globular domain; and
this second part contains another polypeptide.
a) полипептида, имеющего последовательность аминокислотных остатков 99-140 SEQ ID NO:2 или SEQ ID NO:44;
b) полипептида, имеющего последовательность аминокислотных остатков 140- или 141-281 SEQ ID NO:2 или SEQ ID NO:44;
c) полипептида, имеющего последовательность аминокислотных остатков 99-281 SEQ ID NO:2 или SEQ ID NO:44.8. The hybrid protein according to claim 7, characterized in that said first part is selected from the group consisting of:
a) a polypeptide having a sequence of amino acid residues 99-140 of SEQ ID NO: 2 or SEQ ID NO: 44;
b) a polypeptide having an amino acid residue sequence 140- or 141-281 of SEQ ID NO: 2 or SEQ ID NO: 44;
c) a polypeptide having the sequence of amino acid residues 99-281 of SEQ ID NO: 2 or SEQ ID NO: 44.
a) последовательности нуклеотидов от нуклеотида 465 до нуклеотида 688 SEQ ID NO:1;
b) последовательности нуклеотидов от нуклеотида 688 до нуклеотида 1016 SEQ ID NO:1;
c) последовательности нуклеотидов от нуклеотида 691 до нуклеотида 1016 SEQ ID NO:1;
d) последовательности нуклеотидов от нуклеотида 465 до нуклеотида 1016 SEQ ID NO:1;
e) последовательности нуклеотидов от нуклеотида 364 до нуклеотида 490 SEQ ID NO:43;
f) последовательности нуклеотидов от нуклеотида 490 до нуклеотида 912 SEQ ID NO:43;
g) последовательности нуклеотидов от нуклеотида 364 до нуклеотида 912 SEQ ID NO:43;
h) последовательности нуклеотидов от нуклеотида 364 до нуклеотида 490 SEQ ID NO:43;
i) полинуклеотида, кодирующего полипептид, имеющий последовательность аминокислотных остатков, которая по меньшей мере на 75% идентична по последовательности аминокислот аминокислотным остаткам 99-, 140- или 141-281 SEQ ID NO:2;
j) полинуклеотида, кодирующего полипептид, имеющий последовательность аминокислотных остатков, по меньшей мере на 75% идентичную по последовательности аминокислот аминокислотным остаткам 99-140 SEQ ID NO:2;
k) последовательностей нуклеотидов, комплементарных а), b), с), d), е), f), g), h), i) или j), и
l) вырожденных последовательностей нуклеотидов а), b), с), d), е), f), g), h), i), j) или k).27. Selected polynucleotide selected from the group consisting of:
a) nucleotide sequences from nucleotide 465 to nucleotide 688 SEQ ID NO: 1;
b) nucleotide sequences from nucleotide 688 to nucleotide 1016 of SEQ ID NO: 1;
c) nucleotide sequences from nucleotide 691 to nucleotide 1016 of SEQ ID NO: 1;
d) nucleotide sequences from nucleotide 465 to nucleotide 1016 of SEQ ID NO: 1;
e) nucleotide sequences from nucleotide 364 to nucleotide 490 of SEQ ID NO: 43;
f) nucleotide sequences from nucleotide 490 to nucleotide 912 of SEQ ID NO: 43;
g) nucleotide sequences from nucleotide 364 to nucleotide 912 SEQ ID NO: 43;
h) nucleotide sequences from nucleotide 364 to nucleotide 490 of SEQ ID NO: 43;
i) a polynucleotide encoding a polypeptide having an amino acid residue sequence that is at least 75% identical in amino acid sequence to amino acid residues 99, 140, or 141-281 SEQ ID NO: 2;
j) a polynucleotide encoding a polypeptide having an amino acid sequence that is at least 75% identical in amino acid sequence to amino acid residues 99-140 of SEQ ID NO: 2;
k) nucleotide sequences complementary to a), b), c), d), e), f), g), h), i) or j), and
l) degenerate nucleotide sequences a), b), c), d), e), f), g), h), i), j) or k).
a) полипептида, содержащего последовательность аминокислотных остатков, которая является по меньшей мере на 75% идентичной по последовательности аминокислот аминокислотным остаткам 26-281 SEQ ID NO:2;
b) полипептида, содержащего последовательность аминокислотных остатков, показанную в SEQ ID NO:2, от аминокислотного остатка 1, 22 или 26 до аминокислотного остатка 281;
c) полипептида, содержащего последовательность аминокислотных остатков, показанную в SEQ ID NO:44, от аминокислотного остатка 1, 22 или 26 до аминокислотного остатка 281;
d) части полипептида zsig37, показанной в SEQ ID NO:2 или SEQ ID NO:44, содержащей коллагеноподобный домен или часть коллагеноподобного домена, способную к димеризации или олигомеризации;
e) части полипептида zsig37, показанной в SEQ ID NO:2 или SEQ ID NO:44, содержащей подобный глобулярному домен или активную часть подобного глобулярному домена; или
f) части полипептида zsig37, показанной в SEQ ID NO:2 или SEQ ID NO:44, включающей в себя коллагеноподобный домен и глобулярный домен; и
указанная вторая часть содержит другой полипептид.28. The selected polynucleotide encoding a hybrid protein consisting essentially of the first part and the second part connected by a peptide bond, the first part being selected from the group consisting of:
a) a polypeptide containing a sequence of amino acid residues that is at least 75% identical in amino acid sequence to amino acid residues 26-281 of SEQ ID NO: 2;
b) a polypeptide containing the sequence of amino acid residues shown in SEQ ID NO: 2, from amino acid residue 1, 22 or 26 to amino acid residue 281;
c) a polypeptide containing the sequence of amino acid residues shown in SEQ ID NO: 44, from amino acid residue 1, 22 or 26 to amino acid residue 281;
d) a portion of the zsig37 polypeptide shown in SEQ ID NO: 2 or SEQ ID NO: 44 containing a collagen-like domain or a portion of a collagen-like domain capable of dimerization or oligomerization;
e) a portion of the zsig37 polypeptide shown in SEQ ID NO: 2 or SEQ ID NO: 44, containing a globular-like domain or an active portion of a globular-like domain; or
f) a portion of the zsig37 polypeptide shown in SEQ ID NO: 2 or SEQ ID NO: 44, including a collagen-like domain and a globular domain; and
this second part contains another polypeptide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5315497P | 1997-07-18 | 1997-07-18 | |
US60/053,154 | 1997-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000103824A true RU2000103824A (en) | 2001-12-10 |
RU2218402C2 RU2218402C2 (en) | 2003-12-10 |
Family
ID=21982287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000103824/13A RU2218402C2 (en) | 1997-07-18 | 1998-07-17 | Isolated polypeptide showing homology relatively to complement-related adipocyte protein (variants), hybrid protein (variants), expressing vector, method for preparing polypeptide, polyclonal antibody, fragment of isolated polynucleotide (variants) |
Country Status (18)
Country | Link |
---|---|
US (2) | US6265544B1 (en) |
EP (1) | EP1002075B1 (en) |
JP (1) | JP3762220B2 (en) |
KR (1) | KR100385868B1 (en) |
CN (1) | CN1201003C (en) |
AT (1) | ATE327328T1 (en) |
AU (1) | AU743745B2 (en) |
BR (1) | BR9810917A (en) |
CA (1) | CA2296530A1 (en) |
DE (1) | DE69834643T2 (en) |
DK (1) | DK1002075T3 (en) |
ES (1) | ES2264207T3 (en) |
HU (1) | HUP0003762A3 (en) |
IL (1) | IL134011A0 (en) |
NO (1) | NO20000215L (en) |
PL (1) | PL338139A1 (en) |
RU (1) | RU2218402C2 (en) |
WO (1) | WO1999004000A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6566499B1 (en) * | 1997-07-18 | 2003-05-20 | Zymogenetics, Inc. | Adipocyte-specific protein homologs |
WO1999004000A1 (en) * | 1997-07-18 | 1999-01-28 | Zymogenetics, Inc. | Adipocyte-specific protein homologs |
FR2767135B1 (en) | 1997-08-06 | 2002-07-12 | Genset Sa | LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF |
US20030129691A1 (en) * | 1998-02-09 | 2003-07-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7300774B1 (en) * | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
CN1341027A (en) * | 1999-02-19 | 2002-03-20 | 津莫吉尼蒂克斯公司 | Inhibitors for use in hemostasis and immune function |
US20040014650A1 (en) * | 2002-07-17 | 2004-01-22 | Sheppard Paul D | Methods for enhancing wound repair |
US6544946B1 (en) * | 1999-02-19 | 2003-04-08 | Zymogenetics, Inc. | Inhibitors for use in hemostasis and immune function |
US20050042719A1 (en) * | 1999-05-27 | 2005-02-24 | Zymogenetics, Inc. | Adipocyte complement related protein homolog zacrp5 |
WO2000073444A1 (en) * | 1999-05-27 | 2000-12-07 | Zymogenetics, Inc. | Adipocyte complement related protein homolog zacrp5 |
AU5037100A (en) * | 1999-05-27 | 2000-12-18 | Zymogenetics Inc. | Adipocyte complement related protein homolog zacrp6 |
DE60043322D1 (en) * | 1999-06-15 | 2009-12-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids for their coding |
MXPA01013444A (en) * | 1999-07-01 | 2002-07-22 | Zymogenetics Inc | Secreted protein zacrp4. |
DE19963859A1 (en) * | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- or oligomer of a di-, tri-, quattro- or pentamer of recombinant fusion proteins |
WO2002070704A2 (en) * | 2000-11-29 | 2002-09-12 | Zymogenetics, Inc. | Adipocyte complement related protein zacrp11 |
CA2433841A1 (en) | 2001-01-16 | 2002-08-29 | Mary Ruth Erickson | Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof |
AU2002249521B2 (en) | 2001-01-16 | 2007-06-21 | Serono Genetics Institute S.A. | Discriminative nucleic acid analysis using clone sequence signatures |
US20030220253A1 (en) * | 2002-03-08 | 2003-11-27 | Lasser Gerald W. | Inhibitors for use in hemostasis |
JP2008507591A (en) * | 2004-05-21 | 2008-03-13 | ゼンコー・インコーポレイテッド | C1q family member proteins with altered immunogenicity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8116494A (en) * | 1993-11-12 | 1995-06-13 | Kenichi Matsubara | Gene signature |
US5869330A (en) | 1995-06-05 | 1999-02-09 | Whitehead Institute For Biomedical Research | DNA encoding a novel serum protein produced exclusively in adipocytes |
WO1999004000A1 (en) * | 1997-07-18 | 1999-01-28 | Zymogenetics, Inc. | Adipocyte-specific protein homologs |
IL136216A0 (en) * | 1997-12-03 | 2001-05-20 | Genentech Inc | Polypeptides and nucleic acids encoding the same |
-
1998
- 1998-07-17 WO PCT/US1998/014864 patent/WO1999004000A1/en not_active Application Discontinuation
- 1998-07-17 EP EP98934630A patent/EP1002075B1/en not_active Expired - Lifetime
- 1998-07-17 JP JP2000503206A patent/JP3762220B2/en not_active Expired - Fee Related
- 1998-07-17 RU RU2000103824/13A patent/RU2218402C2/en not_active IP Right Cessation
- 1998-07-17 ES ES98934630T patent/ES2264207T3/en not_active Expired - Lifetime
- 1998-07-17 DE DE69834643T patent/DE69834643T2/en not_active Expired - Fee Related
- 1998-07-17 US US09/118,408 patent/US6265544B1/en not_active Expired - Lifetime
- 1998-07-17 IL IL13401198A patent/IL134011A0/en unknown
- 1998-07-17 AU AU84113/98A patent/AU743745B2/en not_active Ceased
- 1998-07-17 AT AT98934630T patent/ATE327328T1/en not_active IP Right Cessation
- 1998-07-17 CN CNB988089114A patent/CN1201003C/en not_active Expired - Fee Related
- 1998-07-17 BR BR9810917-0A patent/BR9810917A/en not_active Application Discontinuation
- 1998-07-17 DK DK98934630T patent/DK1002075T3/en active
- 1998-07-17 KR KR10-2000-7000538A patent/KR100385868B1/en not_active IP Right Cessation
- 1998-07-17 CA CA002296530A patent/CA2296530A1/en not_active Abandoned
- 1998-07-17 HU HU0003762A patent/HUP0003762A3/en unknown
- 1998-07-17 PL PL98338139A patent/PL338139A1/en not_active IP Right Cessation
-
2000
- 2000-01-17 NO NO20000215A patent/NO20000215L/en not_active Application Discontinuation
-
2001
- 2001-07-23 US US09/911,176 patent/US6518403B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000103824A (en) | Adipocyte-Specific Protein Homologues | |
RU2218402C2 (en) | Isolated polypeptide showing homology relatively to complement-related adipocyte protein (variants), hybrid protein (variants), expressing vector, method for preparing polypeptide, polyclonal antibody, fragment of isolated polynucleotide (variants) | |
KR860001305B1 (en) | Expression linkers | |
CA2339889A1 (en) | Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests | |
RU2198179C2 (en) | Modified signal peptide of escherichia coli enterotoxin-ii and microorganism expressing fusion protein of mentioned peptide with heterological protein | |
CA2339331A1 (en) | Expression and export of angiogenesis inhibitors as immunofusins | |
KR960704038A (en) | Cytokines That Bind the Cell Surface Receptor Hek | |
EP0651761A1 (en) | Method for modification of recombinant polypeptides | |
WO1999055868A3 (en) | Fizz proteins | |
GB2272698A (en) | Fusion peptides which bind to streptavidin | |
JPH02501112A (en) | Purification method by immunoaffinity | |
CA2337100A1 (en) | Polypeptides of lymphodendritic cell adhesion molecules (ldcams) and polynucleotides encoding the same | |
Liew et al. | Preparation of recombinant thioredoxin fused N-terminal proCNP: analysis of enterokinase cleavage products reveals new enterokinase cleavage sites | |
Johnson et al. | Identification of a plastid-specific ribosomal protein in the 30 S subunit of chloroplast ribosomes and isolation of the cDNA clone encoding its cytoplasmic precursor. | |
RU2000123559A (en) | CHITIN-BINDING CHITINASE FRAGMENTS | |
WO2000026244A3 (en) | A novel tumor necrosis factor family member, drl, and related compositions and methods | |
KR870001311A (en) | Methods of Making Proteins and Polypeptides | |
CA2273196A1 (en) | Isolated mammalian monocyte cell genes; related reagents | |
JP3781771B2 (en) | Novel polypeptide and DNA encoding the same | |
AU8640798A (en) | Recombinant expression of insulin c-peptide | |
CA2324513A1 (en) | Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production | |
US7390639B2 (en) | Staphylococcal nuclease fusion proteins for the production of recombinant peptides | |
CA2000309A1 (en) | Recombinant pdgf and methods for production | |
Emery et al. | The p24 family of transmembrane proteins at the interface between endoplasmic reticulum and Golgi apparatus | |
EP0527778B1 (en) | Improved process of purifying recombinant proteins and compounds useful in such process |